Immunocore  

Gaithersburg,  MD 
United States
https://www.immunocore.com/
  • Booth: 13041

Immunocore is a commercial-stage biotechnology company with a mission to radically improve outcomes for patients living with cancer, infectious diseases, and autoimmune conditions by pioneering and delivering transformative medicines. In 2022 we launched the world’s first T cell receptor (TCR) therapy, ushering in a new era of cancer therapeutics. By unlocking >90% of cancer targets, our modular and off-the-shelf ImmTAC technology is designed to harness the natural immune system's power to fight multiple cancers and help address unmet needs.

 Products

  • Immunocore Pipeline
    Built on our proprietary ImmTAX (Immune Mobilizing Monoclonal TCRs Against X disease) platform, we have a diverse pipeline of bispecific therapies across a broad range of indications.

    Our pipeline includes clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects.
    In cancer, our ImmTAC molecules are designed to recognize and bind to the chosen target antigen presented by the cell (through an HLA complex). Then the recruiting arm (an anti-CD3 effector function) engages T cells to kill the cancer cell through lytic processes.

    We currently have three Phase 3 trials in melanoma indications; Phase 1/2 trial arms in ovarian cancer and non-small cell lung cancer; and a Phase 1 trial for colorectal and gastrointestinal cancers. We also have a half-life extended candidate in multiple solid tumors.

    CM-US--2400002 ...

Categories

Cancer Types
  • Gastrointestinal (Colorectal) Cancer
  • Gastrointestinal (Noncolorectal) Cancer
  • Gynecologic Cancer
  • Lung Cancer
  • Melanoma/Skin Cancers
  • Metastatic Disease
    • Categories:
  • Immunotherapy
    • Loading ...

    :
    :


    Legend
    Available Timeslot
    Scheduled Appointment
    Personal Appointments
    Request
    Blocked Timeslot
    Restricted Timeslot
    Cancelled
    Declined